HealthyPhase 1LBLNCT05964647
Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects
A Phase 1 study testing LSD (150 µg) + ketanserin (40 mg), LSD (150 µg) + olanzapine (10 mg) and LSD (150 µg) + lorazepam (2 mg) in people with Healthy, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
Trial summary
The main objective of this study is to determine whether administration of ketanserin (40 mg), olanzapine (10 mg), and lorazepam (2 mg) after administration of LSD (150 µg) attenuates and shortens the subjective LSD response (any drug effect) compared to administration of LSD (150 µg) alone Read more about this study
- Who is it for?
- Ages 25 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- LSD (150 µg) + ketanserin (40 mg), LSD (150 µg) + olanzapine (10 mg) and LSD (150 µg) + lorazepam (2 mg)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 20 participants
- Where
- 1 siteSwitzerland
- Study dates
- 1 Feb 2024to 30 Jun 2025
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age between 25 and 65 years
- Sufficient understanding of the German language
- Understanding of procedures and risks associated with the study
- Willing to adhere to the protocol and signing of the consent form
- Willing to refrain from the consumption of illicit psychoactive substances during the study
- Abstaining from xanthine-based liquids and foods from the evenings prior to the study sessions to the end of the study days, limit coffee drinking ≤ 3 cups per day for 7 days prior to study day
Show all 10Show fewer
- Participants must be willing not to drive a traffic vehicle or to operate machines within 48 h after substance administration
- Willing to use effective contraceptive measures throughout study participation (according to Clinical Trial Facilitation Group (CTFG): Recommendations related to contraception and pregnancy testing in clinical trials)
- Women of childbearing potential must have a negative pregnancy test at the beginning of the study. Pregnancy tests are repeated before each study session.
- Body mass index between 18 - 29 kg/m2
Who cannot join
- Chronic or acute medical condition
- Current or previous major psychiatric disorder including psychotic disorder, mania / hypomania, borderline personality disorders.
- Psychotic disorder or bipolar disorder in first-degree relatives
- Known hypersensitivity to LSD, ketanserin, olanzapine or lorazepam
- Hypertension (>140/90 mmHg) or hypotension (SBP < 85 mmHg)
- Hallucinogenic substance use (not including cannabis) more than 10 times or any time within the previous two months
Show all 15Show fewer
- Pregnancy or current breastfeeding
- Participation in another clinical trial (currently or within the last 30 days)
- Use of medication that may interfere with the effects of the study medication
- Current substance use disorder (within the last 2 months)
- Tobacco smoking (>1 cigarette/day)
- Consumption of alcoholic beverages (>15 drinks/week)
- Not exhibiting consistent startle responding on the screening day (i.e., over 75% discernible responses to six 108 dB 40 ms startle pulses), as this would preclude the ability to measure fear potentiated startle.
- Use of strong CYP2D6 inhibitor
- Use of strong CYP1A2 inhibitor or inducer
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
University Hospital Basel
Basel, Canton of Basel-City, 4055
About this study
The main objective of this study is to determine whether administration of ketanserin (40 mg), olanzapine (10 mg), and lorazepam (2 mg) after administration of LSD (150 µg) attenuates and shortens the subjective LSD response (any drug effect) compared to administration of LSD (150 µg) alone
Read the detailed description
LSD is investigated as treatment for various psychiatric (e.g., depression and anxiety) but also somatic disorders (e.g., cluster headache). In Switzerland, compassionate use of psychedelics including LSD is possible based on single authorizations of the federal office of public health in treatment-resistant patients. Additionally, current social and political changes demonstrate a shift of how psychedelics are seen and how they might be used in therapy in the future.
Despite the good safety profile of LSD, a broader use might increase the number of adverse psychological reactions to LSD. For such occasions, health professionals should have a tool to not only psychologically but also pharmacologically interfere and end states of acute psychedelic-induced distress. In clinical practice, the gamma-butyric acid (GABA) agonistic acting benzodiazepine lorazepam or the atypical neuroleptic olanzapine with affinity to the 5-HT2A, 5-HT2C and dopamine D1-4 receptors are primarily used for the treatment of drug-induced psychotic symptoms. However, the ability of these drugs to block these effects after LSD intake remains to be investigated.
The primary goal of the present study is therefore to investigate whether ketanserin, olanzapine and lorazepam administration after LSD administration might attenuate and shorten the LSD response compared to administration of LSD alone. Additionally, the present study examines changes in quality of the LSD experience after administration of ketanserin, olanzapine or lorazepam and effects on sensorimotor gating and sleep. The study provides insight into the receptor mechanisms involved in alterations of consciousness and specifically the relevance of ongoing 5-HT2A receptor stimulation in the mediation of the psychedelic response to LSD and psychotic symptoms.
- Conditions
- Healthy
- Being tested
- LSD (150 µg) + ketanserin (40 mg), LSD (150 µg) + olanzapine (10 mg), LSD (150 µg) + lorazepam (2 mg), LSD (150 µg) + placebo, Placebo + placebo
- Keywords
- LSD, Serotonin, Psychedelics
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LSD (150 µg) + ketanserin (40 mg)Drug
Drug: LSD (150 µg) per os, single dose
Other: Ketanserin (40 mg) per os, single dose
LSD (150 µg) + olanzapine (10 mg)Drug
Drug: LSD (150 µg) per os, single dose
Other: Olanzapine (10 mg) per os, single dose
LSD (150 µg) + lorazepam (2 mg)Drug
Drug: LSD (150 µg) per os, single dose
Other: Lorazepam (2 mg) per os, single dose
LSD (150 µg) + placeboDrug
Drug: LSD (150 µg) per os, single dose
Other: Placebo (Capsules containing mannitol looking identical to the other drugs)
Placebo + placeboDrug
Drug: Placebo (Capsules containing mannitol looking identical to the other drugs)
Other: Placebo (Capsules containing mannitol looking identical to the other drugs)
| Study group | Role | What they receive |
|---|---|---|
| LSD + ketanserin | Active comparator | Not described Receives: Drug: LSD (150 µg) + ketanserin (40 mg) |
| LSD+ olanzapine | Active comparator | Not described Receives: Drug: LSD (150 µg) + olanzapine (10 mg) |
| LSD+ lorazepam | Active comparator | Not described Receives: Drug: LSD (150 µg) + lorazepam (2 mg) |
| LSD + placebo | Active comparator | Not described Receives: Drug: LSD (150 µg) + placebo |
| Placebo + placebo | Placebo comparator | Not described Receives: Drug: Placebo + placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Duration of subjective response
Visual Analog Scales (VAS) will be repeatedly used to assess subjective alterations in consciousness over time. VAS will be presented as 100 mm long horizontal lines marked with: "not at all" on the left and any drug effect", "good drug effect", "bad drug effect", "stimulated", "tiredness", "fear", "nausea", "alteration of vision", "alteration of hearing", "sounds seem to influence what I see", "alteration of sense of time", "the boundaries between myself and my surroundings seem to blur", "I gain insights into contexts that were previously mysterious to me", "opposites dissolve", "talkative", "happy", and "trust". Additionally, "my perception is…" from "muted" to "clear", "I feel …" from "relaxed" to "tense", and "I feel my thoughts are …" from "sluggish" to "racing". Subjects will mark the scale with vertical lines.
Measured: 18 months
Extent of subjective response
Area under the curve (AUEC), Emax, of the VAS-Item "any drug effect"
Measured: 18 months
Secondary outcomes (29)
Alterations of consciousness
Altered States of Consciousness 5 Dimensions of Altered States of Consciousness (5D-ASC) assesses mood, anxiety, derealization, depersonalization, changes in perception, auditory alterations, and reduced vigilance. The questionnaire is consisting of 94 items to be rated on a visual analog scale (horizontal line, 100 mm, marked with "not at all" on the left and "extremely" on the right), with higher values indicating stronger effects. Subjects will mark the scale with vertical lines.
Measured: 18 months
Mystical-type effects
Mystical-type experience questionnaire (MEQ) assesses with 30 items (embedded into the SCQ) the mystical experiences on a 6-point Likert scale ranging from 0 ("not at all") to 5 ("extremely").
Measured: 18 months
Subjective effects I
Visual Analog Scales (VAS) will be repeatedly used to assess subjective alterations in consciousness over time. VAS will be presented as 100 mm long horizontal lines marked with: "not at all" on the left and any drug effect", "good drug effect", "bad drug effect", "stimulated", "tiredness", "fear", "nausea", "alteration of vision", "alteration of hearing", "sounds seem to influence what I see", "alteration of sense of time", "the boundaries between myself and my surroundings seem to blur", "I gain insights into contexts that were previously mysterious to me", "opposites dissolve", "talkative", "happy", and "trust". Additionally, "my perception is…" from "muted" to "clear", "I feel …" from "relaxed" to "tense", and "I feel my thoughts are …" from "sluggish" to "racing". Subjects will mark the scale with vertical lines.
Measured: 18 months
Subjective effects II
Adjective Mood Rating Scale (AMRS) assesses the occurrence and intensity of 60 moods on a 4-point Likert scale ranging from "not at all" to "extremely".
Measured: 18 months
Subjective effects III
The Addiction Research Center Inventory (ARCI) is a true-false questionnaire with five empirically derived scales. The scale is administered once before, after 3 h, 10 h, and 24 h after LSD administration.
Measured: 24 hours
Psychotomimetic effects I
The aberrant salience inventory (ASI) is a 29-item questionnaire rated as "yes" or "no" measuring trait aberrant salience, which has been hypothesized to be important for psychosis and psychotic disorders. The questionnaire will be administered once at the end of the session and subjects will be instructed to retrospectively rate peak alterations during the study session.
Measured: 18 months
Psychotomimetic effects II
The psychotomimetic states inventory (PSI) consists of 48 items measuring "psychosis-like" experiences and is one of the most widely used measure of drug-induces psychotic-like effects. Items will be scored on a 4-point scale (0 = never to 3 = strongly). The questionnaire will be administered once at the end of the session and subjects will be instructed to retrospectively rate peak alterations during the study session.
Measured: 18 months
Effects of LSD on mindfulness and decentering I
The 39-item Five Facet Mindfulness Questionnaire (FFMQ) measures five facets of a general tendency to be mindful in daily life. The FFMQ will be completed by the participants at screening, the beginning of each study session (to assess respective baseline) and will be handed in to the participants at the end of the respective study visit and participants will be asked to complete the FFMQ at home 36 h after the study drug has been administered.
Measured: 36 hours
Effects of LSD on mindfulness and decentering II
The 20-item Experience Questionnaire (EQ) measures decentering and ruminating. Decentering is defined as looking at one's own feelings from a distance, in an observing and objective way. The EQ will be completed by the participants at screening, at the beginning of each study session (to assess respective baseline) and will be handed in to the participants at the end of the respective study visit, and participants will be asked to complete the EQ at home 36 h after the study drug has been administered
Measured: 36 hours
Challenging experiences
The Challenging Experiences Questionnaire (CEQ) was developed to characterize challenging experiences with psilocybin. The 26-item questionnaire is rated on a 6-point Likert scale ranging from 0 (none, not at all) to 5 (extreme, more than ever before in my life). The CEQ includes seven factors: "Fear"; "Grief"; "Physical Distress"; "Insanity"; "Isolation"; "Death"; "Paranoia", and a total score (Total) is calculated over all items. 9. The validated German version of the CEQ 153 will be administered once at the end of the session and subjects will be instructed to retrospectively rate their experiences during peak alterations during the study session.
Measured: 18 months
Effects on prepulse inhibition and sensorimotor gating
Prepulse inhibition (PPI) of the acoustic startle response is an operational measure of sensorimotor gating that can be measured in animals and humans and serves as a preclinical model for schizophrenia. LSD and other serotonergic 5-HT2A agonists disrupt PPI in animals and in humans and PPI is also disrupted in schizophrenic patients. We will measure effects of LSD on sensorimotor gating function.
Measured: 18 months
Blood pressure
Blood pressure, assessed 21 times during each study session via systolic and diastolic blood pressure.
Measured: 18 months
Heart rate
Heart rate, assessed 21 times during each study session via heart rate, Emax.
Measured: 18 months
Body temperature
Body temperature assessed 20 times during each study session via tympanic body temperature.
Measured: 18 months
Pupil size
Pupil size, assessed 8 times during each study session via pupilometer.
Measured: 18 months
LSD concentrations in the blood
LSD and metabolites concentrations measured in the blood plasma, assessed 17 times during each study session via blood samples.
Measured: 18 months
Ketanserin concentrations in the blood
Ketanserin concentrations measured in the blood plasma, assessed 17 times during each study session via blood samples.
Measured: 18 months
Olanzapine concentrations in the blood
Olanzapine concentrations measured in the blood plasma, assessed 17 times during each study session via blood samples.
Measured: 18 months
Lorazepam concentrations in the blood
Lorazepam concentrations measured in the blood plasma, assessed 17 times during each study session via blood samples.
Measured: 18 months
Effects of LSD on sleep phases
The Dreem® headband will record electroencephalographic (EEG; five dry electrodes yielding seven derivations), acceleration (3D accelerometer), and heart rate (red-infrared pulse oximeter) activity. We will further calculate sleep variables of %REM (REM sleep duration divided by total sleep duration), REM Latency (duration of non-REM sleep before the first REM phase), and REM Efficiency (REM sleep duration divided by the total REM episode duration) for each night. We will start the measurement 11 h after LSD administration until the end of the study day.
Measured: 11 hours
Persisting effects
The 143-item Johns Hopkins University Persisting Effects Questionnaire (PEQ) seeks information about changes in attitude, mood, behavior, and spiritual experience items are rated on a six-point scale. The PEQ will be administered at the EOS visit.
Measured: 18 months
Adverse effects
The adapted list of complaints (LC) consists of 50 items offering a global score measuring physical and general discomfort. The LC list is administered before, 12 h after LSD administration with reference to all complaints arising since the LSD administration, and at the end of the session with reference to complaints throughout the night. Subjects will additionally be asked to report any adverse events during the sessions or/and between study sessions as assessed at the beginning of the next session and at the EOS visit.
Measured: 18 months
Emotional effects
Multifaceted Empathy Test (MET), effects on empathy in computer tests, assessed one time during each study session.
Measured: 18 months
Sleepiness
The Karolinska Sleepiness Scale (KSS) measures the subjective level of sleepiness 161. The scale shows a 10-point scale from "1 - extremely alert" to "10 - extremely sleepy - cannot stay awake". The KSS will be assessed at the beginning and repeatedly in the evening and next morning of the study session
Measured: 18 months
Effect moderation through personality traits I
Assessed one time during the screening via the NEO-Five-Factor-Inventory (NEO-FFI). The NEO-FFI assesses 5 personality traits (openness to experience, conscientiousness, extraversion, agreeableness and neuroticism) consisting of of 60 items. Each item is evaluated on a scale from -- "strong disagreement" to ++ "strong agreement".
Measured: 18 months
Effect moderation through personality traits II
Assessed one time during the screening via Freiburger Personality Inventory (FPI). The FPI-R version comprises 138 items and covers 12 dimensions of personality: life satisfaction, social orientation, performance orientation, inhibition, excitability, aggressiveness, stress, physical complaints, health concerns, openness, as well as the secondary factors according to Eysenck's Extraversion and Emotionality (Neuroticism). It uses a 2-point scale ("true" and "not true").
Measured: 18 months
Effect moderation through personality traits III
Assessed one time during the screening via Saarbrücker Personality Questionnaire (SPF). The SPF defines empathy as the "reactions of one individual to the observed experiences of another." It assesses 28-items on a 5-point Likert scale ranging from "Does not describe me well" to "Describes me very well". The measure has 4 subscales (Perspective Taking, Fantasy, Empathic Concern, Personal Distress) each made up of 7 different items.
Measured: 18 months
Effect moderation through personality traits IV
Assessed one time during the screening via HEXACO personality inventory (Honesty-Humility, Emotionality, Extraversion, Agreeableness, Conscientiousness, and Openness). The HEXACO consists of 100 items. Each item is evaluated on a scale from 1 "strong disagreement" to 5 "strong agreement".
Measured: 18 months
Effect moderation through personality traits V
Assessed one time during the screening via Defense Style Questionnaire (DSQ-40). The DSQ-40 can provide scores for 20 individual defenses, and scores for the three factors "mature", "neurotic", and "immature". Each item is evaluated on a scale from 1 to 9, where "1" indicates "completely disagree" and "9" indicates "fully agree".
Measured: 18 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Jul 2023
- Study start1 Feb 2024
- Primary completion30 Jun 2025
- Study completion30 Jun 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by University Hospital, Basel, SwitzerlandThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Model description
- Crossover Assignment
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Basel, Switzerland
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05964647
- Sponsor's protocol ID
- BASEC ID 2023-01075
- Acronym
- LBL
- Status last verified
- Nov 2025
- First submitted
- 19 Jul 2023
- Last updated
- 17 Nov 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 17 Nov 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Ketanserin, Olanzapine, and Lorazepam After LSD Administration on the Acute Response to LSD in Healthy Subjects
- ClinicalTrials.gov ID
- NCT05964647
- Acronym / sponsor ID
- LBL / BASEC ID 2023-01075
- Conditions
- Healthy
- Keywords
- LSD, Serotonin, Psychedelics
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- University Hospital, Basel, SwitzerlandUniversity, hospital or other
- Study start
- 1 Feb 2024 (actual)
- Primary completion
- 30 Jun 2025 (actual)
- Study completion
- 30 Jun 2025 (actual)
- First posted
- 28 Jul 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main objective of this study is to determine whether administration of ketanserin (40 mg), olanzapine (10 mg), and lorazepam (2 mg) after administration of LSD (150 µg) attenuates and shortens the subjective LSD response (any drug effect) compared to administration of LSD (150 µg) alone
Detailed description
LSD is investigated as treatment for various psychiatric (e.g., depression and anxiety) but also somatic disorders (e.g., cluster headache). In Switzerland, compassionate use of psychedelics including LSD is possible based on single authorizations of the federal office of public health in treatment-resistant patients. Additionally, current social and political changes demonstrate a shift of how psychedelics are seen and how they might be used in therapy in the future.
Despite the good safety profile of LSD, a broader use might increase the number of adverse psychological reactions to LSD. For such occasions, health professionals should have a tool to not only psychologically but also pharmacologically interfere and end states of acute psychedelic-induced distress. In clinical practice, the gamma-butyric acid (GABA) agonistic acting benzodiazepine lorazepam or the atypical neuroleptic olanzapine with affinity to the 5-HT2A, 5-HT2C and dopamine D1-4 receptors are primarily used for the treatment of drug-induced psychotic symptoms. However, the ability of these drugs to block these effects after LSD intake remains to be investigated.
The primary goal of the present study is therefore to investigate whether ketanserin, olanzapine and lorazepam administration after LSD administration might attenuate and shorten the LSD response compared to administration of LSD alone. Additionally, the present study examines changes in quality of the LSD experience after administration of ketanserin, olanzapine or lorazepam and effects on sensorimotor gating and sleep. The study provides insight into the receptor mechanisms involved in alterations of consciousness and specifically the relevance of ongoing 5-HT2A receptor stimulation in the mediation of the psychedelic response to LSD and psychotic symptoms.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 5
- Model description
- Crossover Assignment
| Arm | Type | Receives |
|---|---|---|
| LSD + ketanserin | Active comparator | Drug: LSD (150 µg) + ketanserin (40 mg) |
| LSD+ olanzapine | Active comparator | Drug: LSD (150 µg) + olanzapine (10 mg) |
| LSD+ lorazepam | Active comparator | Drug: LSD (150 µg) + lorazepam (2 mg) |
| LSD + placebo | Active comparator | Drug: LSD (150 µg) + placebo |
| Placebo + placebo | Placebo comparator | Drug: Placebo + placebo |
Who may qualify
- Ages
- 25 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- Age between 25 and 65 years
- Sufficient understanding of the German language
- Understanding of procedures and risks associated with the study
- Willing to adhere to the protocol and signing of the consent form
- Willing to refrain from the consumption of illicit psychoactive substances during the study
Key exclusion criteria (15 listed)
- Chronic or acute medical condition
- Current or previous major psychiatric disorder including psychotic disorder, mania / hypomania, borderline personality disorders.
- Psychotic disorder or bipolar disorder in first-degree relatives
- Known hypersensitivity to LSD, ketanserin, olanzapine or lorazepam
- Hypertension (>140/90 mmHg) or hypotension (SBP < 85 mmHg)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LSD (150 µg) + ketanserin (40 mg)Drug: LSD (150 µg) per os, single dose Other: Ketanserin (40 mg) per os, single dose | Drug | LSD + ketanserin |
| LSD (150 µg) + olanzapine (10 mg)Drug: LSD (150 µg) per os, single dose Other: Olanzapine (10 mg) per os, single dose | Drug | LSD+ olanzapine |
| LSD (150 µg) + lorazepam (2 mg)Drug: LSD (150 µg) per os, single dose Other: Lorazepam (2 mg) per os, single dose | Drug | LSD+ lorazepam |
| LSD (150 µg) + placeboDrug: LSD (150 µg) per os, single dose Other: Placebo (Capsules containing mannitol looking identical to the other drugs) | Drug | LSD + placebo |
| Placebo + placeboDrug: Placebo (Capsules containing mannitol looking identical to the other drugs) Other: Placebo (Capsules containing mannitol looking identical to the other drugs) | Drug | Placebo + placebo |
Primary outcome
Duration of subjective response
Time frame: 18 months
Visual Analog Scales (VAS) will be repeatedly used to assess subjective alterations in consciousness over time. VAS will be presented as 100 mm long horizontal lines marked with: "not at all" on the left and any drug effect", "good drug effect", "bad drug effect", "stimulated", "tiredness", "fear", "nausea", "alteration of vision", "alteration of hearing", "sounds seem to influence what I see", "alteration of sense of time", "the boundaries between myself and my surroundings seem to blur", "I gain insights into contexts that were previously mysterious to me", "opposites dissolve", "talkative", "happy", and "trust". Additionally, "my perception is…" from "muted" to "clear", "I feel …" from "relaxed" to "tense", and "I feel my thoughts are …" from "sluggish" to "racing". Subjects will mark the scale with vertical lines.
Extent of subjective response
Time frame: 18 months
Area under the curve (AUEC), Emax, of the VAS-Item "any drug effect"
29 secondary outcomes
Alterations of consciousness
Time frame: 18 months
Mystical-type effects
Time frame: 18 months
Subjective effects I
Time frame: 18 months
Subjective effects II
Time frame: 18 months
Subjective effects III
Time frame: 24 hours
Psychotomimetic effects I
Time frame: 18 months
Psychotomimetic effects II
Time frame: 18 months
Effects of LSD on mindfulness and decentering I
Time frame: 36 hours
Effects of LSD on mindfulness and decentering II
Time frame: 36 hours
Challenging experiences
Time frame: 18 months
Effects on prepulse inhibition and sensorimotor gating
Time frame: 18 months
Blood pressure
Time frame: 18 months
Heart rate
Time frame: 18 months
Body temperature
Time frame: 18 months
Pupil size
Time frame: 18 months
LSD concentrations in the blood
Time frame: 18 months
Ketanserin concentrations in the blood
Time frame: 18 months
Olanzapine concentrations in the blood
Time frame: 18 months
Lorazepam concentrations in the blood
Time frame: 18 months
Effects of LSD on sleep phases
Time frame: 11 hours
Persisting effects
Time frame: 18 months
Adverse effects
Time frame: 18 months
Emotional effects
Time frame: 18 months
Sleepiness
Time frame: 18 months
Effect moderation through personality traits I
Time frame: 18 months
Effect moderation through personality traits II
Time frame: 18 months
Effect moderation through personality traits III
Time frame: 18 months
Effect moderation through personality traits IV
Time frame: 18 months
Effect moderation through personality traits V
Time frame: 18 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Nov 2025.
- Individual participant dataSharing planned: No
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing LSD (150 µg) + ketanserin (40 mg), LSD (150 µg) + olanzapine (10 mg) and LSD (150 µg) + lorazepam (2 mg) in people with Healthy, run by University Hospital, Basel, Switzerland at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Duration of subjective response (time frame: 18 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Nov 2025.